Account:
Sussex Research Laboratories Inc., leading GalNAc and glycopeptide specialist, is excited to announce sponsorship of TIDES USA 2022: Oligonucleotide & Peptide Therapeutics!
For over 25 years, we have enabled application of complex carbohydrate systems, including GalNAc and glycopeptides, in drug discovery, drug delivery, drug targeting, glycoconjugate vaccine development, immunotherapy, therapeutic enhancement and diagnostic/bio-analytical assay development. Visit us at booth 102 from May 9-12, 2022 at the Hynes Convention Center in Boston, Massachusetts, USA! You can also look us up on the TIDES Connectme app.
About Sussex Research Laboratories Inc.: Sussex Research Laboratories Inc. is a global leader in the design and synthesis of complex carbohydrates and stable isotope-labeled molecules that enable access to systems for the advancement of modern drug discovery and development. Through design, synthesis and characterization of molecules that incorporate glycotechnology, the company’s unique synthesis capabilities and product portfolio of glycans, glycosylated ligands, glycoamino acids, glycopeptides, glycolipids and glycoconjugates enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of peptides, proteins, antibodies, lipids and oligonucleotides. For more information visit www.sussex-research.com.
SHARE THIS ARTICLE ON:
Get product updates and announcements from Sussex Research in your inbox at no charge.
Sussex Research Laboratories Inc. to Attend the 25th Annual San Diego Glycobiology Symposium (SDGS)
March 20, 2023
Sussex Research Laboratories Inc. to Exhibit at the 8th Annual OPT Congress
February 28, 2023
Sussex Research Laboratories Inc. Appoints Dr. Corwin Nycholat to Advisory Board
February 3, 2023
Sussex Research Laboratories Inc. to Exhibit at The American Peptide Symposium 2022 - "Peptide Science at the Summit"
April 26, 2022
Sussex Research Laboratories Inc. / Queen’s University collaboration receives support to develop novel small molecule therapies for COVID-19
May 21, 2020